

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM332493

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
GE Business Capital Corporation	FORMERLY Transamerica Business Credit Corporation	12/02/2010	CORPORATION:
RECEIVING PARTY DATA			
Name:	Dendreon Corporation		
Street Address:	1301 2nd Avenue		
City:	Seattle		
State/Country:	WASHINGTON		
Postal Code:	98101		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	2188041	DACS	
Registration Number:	2530065	DENDREON	
Registration Number:	2465920	DENDREON	
Registration Number:	3616391	DENDREON	
Registration Number:	2545242	PROVENGE	
CORRESPONDENCE DATA			
Fax Number:	2127352000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-735-2811		
Email:	mribando@skadden.com		
Correspondent Name:	Skadden, Arps, Slate, Meagher & Flom		
Address Line 1:	Four Times Square		
Address Line 2:	Monique L. Ribando		
Address Line 4:	New York, NEW YORK 10036		
ATTORNEY DOCKET NUMBER:	180680.3		
NAME OF SUBMITTER:	Monique L. Ribando		
SIGNATURE:	/Monique L. Ribando/		

CH \$140.00 2188041

DATE SIGNED:	02/18/2015
---------------------	------------

Total Attachments: 7

- source=GE Transamerica Security Release Signed#page1.tif
- source=GE Transamerica Security Release Signed#page2.tif
- source=GE Transamerica Security Release Signed#page3.tif
- source=GE Transamerica Security Release Signed#page4.tif
- source=GE Transamerica Security Release Signed#page5.tif
- source=GE Transamerica Security Release Signed#page6.tif
- source=GE Transamerica Security Release Signed#page7.tif

**RELEASE OF
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Agreement is entered into as of this 2nd day of December, 2010, and effective as of February 28, 2004 ("Effective Date"), between GF Business Capital Corporation, formerly known as Transamerica Business Capital Corporation, as successor in interest to Transamerica Business Credit Corporation ("Secured Party") and Dendreon Corporation ("Company").

RECITALS

A. Secured Party and Company entered into the Intellectual Property Security Agreement, dated as of August 3, 1999 and the Supplement One to Intellectual Property Security Agreement, dated as of June 6, 2001 (collectively, the "Existing IP Agreement"), pursuant to which Company granted a security interest in favor of Secured Party in and to the Intellectual Property Collateral (as defined in the Existing IP Agreement).

B. Company desires that Secured Party release its security interest in and to the Intellectual Property Collateral upon the terms and conditions set forth in this Agreement.

Therefore, in consideration of these Recitals, any sums to be paid, any rights granted, and the mutual promises contained in this Agreement, the parties agree to the following:

1. RELEASE

1.1 Secured Party, without recourse, representation, warranty or other assurance of any kind, hereby releases and terminates its security interest in the Intellectual Property Collateral, as more particularly described on Exhibits A and B hereto.

2. SECURED PARTY'S REPRESENTATIONS

2.1 Secured Party makes no representations, warranties or other assurances of any kind. In particular, there are no express or implied warranties: (a) of merchantability or fitness for a

particular purpose; or (b) that use of the Intellectual Property Collateral does not infringe any existing trademarks, patents or other intellectual property rights. In addition, nothing in this Agreement may be deemed to be a representation or warranty by Secured Party of the validity of any trademarks and/or trademark applications, patents and/or patent applications or the accuracy, safety, efficacy, or usefulness, for any purpose, of the trademarks and/or trademark applications, patents and/or patent applications constituting Intellectual Property Collateral. Secured Party has no obligation, express or implied, to supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing or sale of any product or service. Secured Party has no liability whatsoever to Company, or any third parties, for or on account of any injury, loss, or damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or any other liability incurred by or imposed upon Company or any other person or entity, arising out of or in connection with or resulting from:

- (i) the production, use, practice, lease, or sale of any product or service;
- (ii) the use of the rights granted to Company herein; or
- (iii) any advertising or other promotional activities with respect to any of the foregoing.

3. MISCELLANEOUS

3.1 This Agreement is entered into in the State of Illinois and must be interpreted in accordance with and its performance governed by the laws of the State of Illinois without reference to its conflicts of laws provisions.

[This space left blank intentionally.]

4 - Entire Understanding

4.1 This Agreement represents the entire understanding between the parties, and supersedes all other agreements, express or implied, between the parties concerning the subject matter hereof, and is not subject to any change or modification except by the execution of a written instrument subscribed to by authorized representatives of the parties.

IN WITNESS WHEREOF, the parties have executed this Agreement as of
December 2, 2010.

Secured Party:

GE BUSINESS CAPITAL CORPORATION (FORMERLY KNOWN AS
TRANSAMERICA BUSINESS CAPITAL CORPORATION, AS SUCCESSOR IN
INTEREST TO TRANSAMERICA BUSINESS CREDIT CORPORATION)

By: 
Name: Scott Towers
Title: Duly Authorized Signatory

Company:

DENDREON CORPORATION


By: 
Name: Richard F. Hamm, Jr.
Title: SR, Corporate Development, GC & Secretary

Exhibit A

Trademarks and Trademark Applications

Country	Trademark	Application/Registration No.
United States	DACS	2,188,041
United States	DENDREON	75/283,623
United States	DENDREON	76/165,904
United States	DENDREON	75/282,526
United States	MYLOVENGE	76/028,099
United States	MYZENIUM	75/927,065
United States	NEUVENGE	76/009,430
United States	NEUZENIUM	75/927,050
United States	PROVENGE	75/927,064
United States	PROZENIUM	75/906,694
Canada	MYLOVENGE	1,071,645
Canada	PROVENGE	1,071,470
European Community	MYLOVENGE	1,817,899
European Community	PROVENGE	1,816,974

Exhibit B

Patents and Patent Applications

Title	Filing Date	Application No.	Country	Patent No.
METHODS FOR ENRICHING CD34+ HUMAN HEMATOPOIETIC PROGENITOR CELLS	08-31-1994	08/299,469	United States	5,474,687
SEPARATION APPARATUS AND METHOD	12-11-1995	08/570,397	United States	5,663,051
REAGENT FOR CELL SEPARATION	04-09-1986	06/849,819	United States	4,927,749
CELL SEPARATION PROCESS	03-25-1987	07/049,863	United States	4,927,750
CENTRIFUGATION SYRINGE, SYSTEM AND METHOD	08-31-1994	08/298,882	United States	5,577,513
METHODS FOR ENRICHING FETAL CELLS FROM MATERNAL BODY FLUIDS	08-31-1994	08/299,468	United States	5,646,004
METHODS FOR ENRICHING SPECIFIC CELL-TYPES BY DENSITY GRADIENT CENTRIFUGATION	08-31-1994	08/299,467	United States	5,840,502
METHODS FOR ENRICHING BREAST TUMOR CELLS	08-31-1994	08/299,465	United States	5,648,223
POTENT ANTIGEN PRESENTING CELL COMPOSITION	07-12-1995	08/501,987	United States	6,121,044
CELL SEPARATION COMPOSITION	12-11-1995	08/570,120	United States	5,789,148
IMMUNOSTIMULATORY METHOD	12-28-1995	08/579,823	United States	6,080,409
IMMUNOSTIMULATORY COMPOSITION AND METHOD	03-21-1997	08/823,008	United States	
IMMUNOSTIMULATORY COMPOSITIONS	9-3-1998	09/146,283	United States	5,976,546
IMMUNOSTIMULATORY COMPOSITION	06-24-1999	09/344,195	United States	6,210,662
GROWTH ARREST GENE COMPOSITIONS AND METHODS	06-27-1997	08/883,070	United States	5,998,599
CELL WASHING DEVICE AND METHOD	07-17-1998	09/118,326	United States	6,197,579
COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST TUMOR-RELATED ANTIGENS	3-14-2000	09/402,845	United States	
PROCESS FOR MAKING SILANIZED COLLOIDAL SILICA	01-14-1998	09/006,775	United States	6,015,843
PROSTATE TUMOR POLYNUCLEOTIDE COMPOSITIONS AND METHODS OF DETECTION THEREOF	07-09-1998	09/112,096	United States	6,194,152
METHOD FOR PREPARATION AND IN VIVO ADMINISTRATION OF ANTIGEN PRESENTING CELL COMPOSITION	06-01-1998	09/323,880	United States	
SELECTIVE APOPTOSIS OF NEOPLASTIC	08-28-1998	60/098,292	United States	

Title	Filing Date	Application No.	Country	Patent No.
CELLS BY AN HLA-DR SPECIFIC MONOCLONAL ANTIBODY				
SELECTIVE APOPTOSIS OF NEOPLASTIC CELLS BY AN HLA-DR SPECIFIC MONOCLONAL	08-26-1999	09/383,663	United States	
COMPOSITIONS AND METHODS FOR ENHANCEMENT OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RESTRICTED ANTIGEN PRESENTATION	12-14-1998	60/112,324	United States	
COMPOSITIONS AND METHODS FOR ENHANCEMENT OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RESTRICTED ANTIGEN PRESENTATION	12-14-1999	09/461,684	United States	7,148,324
SUPPRESSOR AND PROGENITOR CELLS	11-04-1992	07/971,723	United States	5,985,656
SUPPRESSOR AND PROGENITOR CELLS	11-16-1999	09/442,171	United States	
SUPPRESSOR CELLS	08-17-1992	07/931,210	United States	
METHODS FOR IN VIVO T CELL ACTIVATION BY ANTIGEN-PULSED DENDRITIC CELLS	12-20-1995	08/575,432	United States	
METHODS FOR USING DENDRITIC CELLS TO ACTIVATE T CELLS	9-6-1994	08/301,157	United States	
METHODS FOR IN VIVO T CELL ACTIVATION BY ANTIGEN-PULSED DENDRITIC CELLS	12-20-1995	08/575,432	United States	
METHODS FOR USING DENDRITIC CELLS TO ACTIVATE GAMMA/DELTA-T CELL RECEPTOR-POSITIVE T CELLS	12-01-1993	08/160,571	United States	
METHODS FOR USING DENDRITIC CELLS TO ACTIVATE GAMMA/DELTA-T CELL RECEPTOR-POSITIVE T CELLS	02-28-1996	08/610,195	United States	6,821,778
IDIOTYPIC VACCINATION AGAINST B CELL LYMPHOMA	03-14-1990	07/493,511	United States	
GENERATION AND CHARACTERIZATION OF A DENDRITIC CELL ISOLATED FROM HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS	10-8-1999	60/158,618	United States	
GENERATION AND CHARACTERIZATION OF A DENDRITIC CELL ISOLATED FROM HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS	10-6-2000	09/684,308	United States	

Title	Filing Date	Application No.	Country	Patent No.
CRYOPRESERVATION OF ANTIGEN-LOADED DENDRITIC CELLS AND THEIR PRECURSORS IN SERUM-FREE MEDIA	12-3-1999	60/168,991	United States	
CRYOPRESERVATION OF ANTIGEN-LOADED DENDRITIC CELLS AND THEIR PRECURSORS IN SERUM-FREE MEDIA	12-1-2000	09/728,424	United States	
COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY	3-30-2000	60/193,504	United States	
COMPOSITIONS AND METHODS FOR DENDRITIC CELL-BASED IMMUNOTHERAPY	3-30-2001	09/821,883	United States	7,060,279